PRECISION BIOSCIENCES INC
For the period ended Mar 31, 2025. Filed May 15, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 15, 2025
DTIL$9.50-1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
(In thousands)
| For the Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows used in operating activities: | ||
| Net (loss) income | $(20,565) | $8,588 |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 395 | 1,143 |
| Share-based compensation | 2,822 | 2,906 |
| Loss on disposal of assets | 9 | 65 |
| Non-cash interest expense | 132 | 227 |
| Amortization of right-of-use assets | 310 | 284 |
| (Gain) loss on changes in fair value | (49) | 348 |
| Gain from equity method investment | (1,342) | (1,713) |
| Amortization of discount on note receivable | (273) | (114) |
| Loss (gain) on change in fair value of warrant liability | 804 | (10,386) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses | 1,850 | (3,277) |
| Marketable securities | 464 | — |
| Accounts receivable | 225 | 511 |
| Contract asset | 1,469 | (1,359) |
| Other assets and other current assets | 259 | (57) |
| Accounts payable | (106) | (2,102) |
| Other liabilities and other current liabilities | (5,118) | (5,837) |
| Deferred revenue | (25) | (7,945) |
| Lease liabilities | (313) | (263) |
| Net cash used in operating activities | (19,052) | (18,981) |
| Cash flows used in investing activities: | ||
| Purchases of property, equipment and software | (64) | (86) |
| Purchases of intangible assets | (250) | — |
| Proceeds from sale of equipment | — | 60 |
| Net cash used in investing activities | (314) | (26) |
| Cash flows provided by financing activities: | ||
| Proceeds from employee stock purchase plan | 140 | 112 |
| Proceeds from issuance of common stock and warrants through underwritten offering, net of issuance cost | — | 37,534 |
| Proceeds from issuance of common stock through ATM facility, net of issuance cost | 9,516 | 1,544 |
| Proceeds from issuance of common stock to collaboration partners and licensees | 1,031 | 905 |
| Net cash provided by financing activities | 10,687 | 40,095 |
| Net (decrease) increase in cash and cash equivalents | (8,679) | 21,088 |
| Cash, cash equivalents, and restricted cash — beginning of period | 108,468 | 116,678 |
| Cash, cash equivalents, and restricted cash — end of period | $99,789 | $137,766 |
| Reconciliation of cash, cash equivalents and restricted cash | ||
| Cash and cash equivalents | $77,223 | $137,766 |
| Restricted cash | $22,566 | $— |
| Total of cash, cash equivalents and restricted cash | $99,789 | $137,766 |
| Supplemental disclosures of cash flow information: | ||
| Property, equipment and software additions included in accounts payable and other current liabilities | $1 | $6 |
| Cash paid for interest | $340 | $526 |
Precision BioSciences, Inc.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.